Skip to main content
Log in

Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Study design and outcomes.

References

  1. Busemann C, Ribback S, Zimmermann K, Sailer V, Kiefer T, Schmidt CA, et al. Toxoplasmosis after allogeneic stem cell transplantation-a single centre experience. Ann Hematol. 2012;91:1081–9.

    Article  PubMed  Google Scholar 

  2. Paccoud O, Guitard J, Labopin M, Surgers L, Malard F, Battipaglia G, et al. Features of toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting. Bone Marrow Transpl. 2020;55:93–99.

    Article  CAS  Google Scholar 

  3. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363:1965–76.

    Article  CAS  PubMed  Google Scholar 

  4. Hakko E, Ozkan HA, Karaman K, Gulbas Z. Analysis of cerebral toxoplasmosis in a series of 170 allogeneic hematopoietic stem cell transplant patients. Transpl Infect Dis. 2013;15:575–80.

    Article  CAS  PubMed  Google Scholar 

  5. Fricker-Hidalgo H, Bulabois C-E, Brenier-Pinchart M-P, Hamidfar R, Garban F, Brion J-P, et al. Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. Clin Infect Dis. 2009;48:e9–e15.

    Article  PubMed  Google Scholar 

  6. Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R, et al. Early detection of toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis. 2005;40:67–78.

    Article  PubMed  Google Scholar 

  7. Robin C, Leclerc M, Angebault C, Redjoul R, Beckerich F, Cabanne L, et al. Toxoplasmosis as an early complication of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2019;25:2510–3.

    Article  CAS  Google Scholar 

  8. Meers S, Lagrou K, Theunissen K, Dierickx D, Delforge M, Devos T, et al. Myeloablative conditioning predisposes patients for toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin Infect Dis. 2010;50:1127–34.

    Article  PubMed  Google Scholar 

  9. Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transpl. 1994;13:549–57.

    CAS  Google Scholar 

  10. Derouin F, Devergie A, Auber P, Gluckman E, Beauvais B, Garin YJ, et al. Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. Clin Infect Dis. 1992;15:267–70.

    Article  CAS  PubMed  Google Scholar 

  11. Aerts R, Mehra V, Groll AH, Martino R, Lagrou K, Robin C, et al. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(23)00495-4 (2023).

  12. Adekunle RO, Sherman A, Spicer JO, Messina JA, Steinbrink JM, Sexton ME, et al. Clinical characteristics and outcomes of toxoplasmosis among transplant recipients at two US academic medical centers. Transpl Infect Dis. 2021;23:e13636.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Isa F, Saito K, Huang Y-T, Schuetz A, Babady NE, Salvatore S, et al. Implementation of molecular surveillance after a cluster of fatal toxoplasmosis at 2 neighboring transplant centers. Clin Infect Dis. 2016;63:565–8.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research work was supported in part by the Cancer Center Support Grant (NCI Grant P30 CA016672).

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: AEM, TA, ES, VM, SA. Data gathering: AEM and TA. Formal analysis: DM. Writing of the original draft: AEM, TA, SA. Review and editing of the final draft: JR, MD, AO, SS, GA, BO, RM, IK, QB, NS, SC, GR, FM, CH, DM, PK, KR, YN, PA, AA, MF, MQ, UP, RC.

Corresponding author

Correspondence to Sairah Ahmed.

Ethics declarations

Competing interests

SC declares Advisory board: Hansa Therapeutics, CareDx, Achrotech, Kiadis Pharma, Allogene, Celularity, MolMed, Phamacyclics; Research funds from Miltenyi Biotech, Kiadis Pharma. GR declares consulting agreement with Omeros Pharma. SA declares research support to institution for clinical trials from Seattle Genetics, Merck, Xencor, Chimagen and Tessa Therapeutics, has membership on Tessa Therapeutic’s and Chimagen scientific advisory committee, she serves on Data Safety Monitoring Board for Myeloid Therapeutics; she is a consultant for ADC therapeutics, KITE/Gilead.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malek, A.E., Al-Juhaishi, T., Milton, D.R. et al. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59, 699–704 (2024). https://doi.org/10.1038/s41409-024-02238-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-024-02238-x

  • Springer Nature Limited

Navigation